Table 4.
Factors associated with 28-day mortality in patients with P. mirabilis bacteremia
| Factors | Survivors N = 51 (%) | Nonsurvivors N = 11 (%) | p value |
|---|---|---|---|
| Age, y, median(IQR) | 71.0 (63.0–79.0) | 73.0 (54.0–84.0) | 0.797 |
| Age ≥ 65 years, n(%) | 32 (62.7) | 7 (63.6) | 1.000 |
| Sex, male, n(%) | 21 (41.2) | 6 (54.6) | 0.51 |
| BMI, kg/m2, median(IQR) | 22.35 (10.07–25.52) | 21.78 (19.15–23.29) | 0.366 |
| ESBL producing pathogen, yes, n(%) | 7 (13.7) | 7 (63.6) | 0.001 |
| Infection source | |||
| Urinary tract infection, n(%) | 28 (54.9) | 4 (36.4) | 0.264 |
| Pneumonia, n(%) | 6 (11.8) | 3 (27.3) | 0.191 |
| Skin and soft tissue infection, n(%) | 2 (3.9) | 0 (0) | 1.000 |
| Biliary infection, n(%) | 8 (15.7) | 1 (9.1) | 1.000 |
| Catheter related infection, n(%) | 2 (3.9) | 1 (9.1) | 0.449 |
| Comorbities | |||
| HTN, n(%) | 33 (64.7) | 5 (45.5) | 0.311 |
| DM, n(%) | 21 (41.2) | 3 (27.3) | 0.505 |
| Cardiovascular disease, n(%) | 5 (9.8) | 3 (27.3) | 0.142 |
| Chronic kidney disease, n(%) | 7 (13.7) | 0 (0) | 0.334 |
| Chronic liver disease, n(%) | 3 (5.9) | 3 (27.3) | 0.063 |
| Rheumatologic disease, n(%) | 2 (3.9) | 0 (0) | 1.000 |
| Solid tumor, n(%) | 26 (51.0) | 6 (54.5) | 0.83 |
| Hematologic malignancy, n(%) | 1 (2.0) | 1 (9.1) | 0.326 |
| Solid organ transplantation, n(%) | 2 (3.9) | 1 (9.1) | 0.449 |
| Charlson score, median(IQR) | 2.0 (1.0–2.0) | 2.0 (1.0–4.0) | 0.239 |
| Predisposing factors | |||
| Neutropenia, n(%) | 2 (4.0) | 0 (0) | 1.000 |
| Chemotherapy, n(%) | 7 (13.7) | 1 (9.1) | 1.000 |
| Nursing home residence, n(%) | 7 (13.7) | 0 (0) | 0.334 |
| Hemodialysis, n(%) | 8 (15.7) | 3 (27.3) | 0.394 |
| Maintaining foley catheter, n(%) | 11 (21.6) | 6 (54.5) | 0.056 |
| Maintaining PEG tube, n(%) | 4 (7.8) | 1 (9.1) | 1.000 |
| ICU care, n(%) | 13 (25.5) | 6 (54.5) | 0.077 |
| Previous antibiotic use, n(%) | 13 (25.5) | 7 (63.6) | 0.029 |
| Cephalosporins, n(%) | 6 (11.8) | 2 (18.2) | 0.623 |
| Carbapenems, n(%) | 3 (5.9) | 1 (9.1) | 0.552 |
| Fluorquinolones, n(%) | 1 (2.0) | 2 (18.2) | 0.079 |
| BLBLI, n(%) | 3 (5.9) | 2 (18.2) | 0.212 |
| Clinical presentation | |||
| Shock, n(%) | 19 (37.3) | 4 (36.4) | 1.000 |
| Acute kidney injury, n(%) | 14 (27.5) | 3 (27.3) | 1.000 |
| APACHE II score, median(IQR) | 11.0 (8.0–16.0) | 17.0 (11.0–19.0) | 0.027 |
| SOFA score, median(IQR) | 2.0 (1.0–5.0) | 5.0 (4.0–8.0) | 0.033 |
| Inappropriate antimicrobial therapy, n(%) | 10 (19.6) | 5 (45.5) | 0.115 |
IQR interquartile range, BMI body mass index, ESBL extended spectrum β-lactamases, HTN hypertension, DM diabetes mellitus, PEG percutaneous endoscopic gastrostomy, ICU intensive care unit, BLBLIs beta-lactam/beta-lactamase inhibitors, APACHE II score Acute Physiology and Chronic Health Evaluation II score, SOFA score the Sequential Organ Failure Assessment score